Session Recording from PHA's 2010 9th International PH Conference
Combination Therapy and Transition to Oral Therapy
June 27, 2010
Treatment options for pulmonary hypertension have dramatically expanded with the availability of multiple medications. If one treatment is good, are two better? When should medication be adjusted or switched, and what evidence is available to guide therapy? This session will focus on the rationale for combination therapy, review results of studies of combination therapy and review transition to oral therapy.
Session Handout (PDF)
The below recording will begin automatically. To view the controls, move your mouse anywhere over the video then move to the control interface at the bottom of the video.
|
Presenter Information
|
| Omar Minai, MD, Cleveland Clinic, Cleveland, Ohio (Chair) |
|
| Nancy Bair, RN, MSN, CNS, Cleveland Clinic, Cleveland, Ohio |
| Joseph Parambil, MD, Cleveland, OH, Cleveland Clinic |
| Namita Sood, MD, FCCP, The Ohio State University, Columbus, Ohio |
| |
DIAMOND
SUPPORTER
|
PLATINUM
SUPPORTER
|
GOLD
SUPPORTER
|
SILVER
SUPPORTER
|
| Actelion Pharmaceuticals US, Inc. |
Gilead Sciences, Inc. |
United Therapeutics Corporation |
Bayer HealthCare |
This is a program of the PHA Medical Education Fund, made possible through unrestricted educational grants from our supporters.